

SUPPLEMENTARY MATERIAL

Risk, clinical course and outcome of ischemic stroke in patients hospitalized with COVID-19: a multicenter cohort study

Sluis WM, Linschoten M, Buijs JE et al

	Title	Page
Figure 1	Flowchart of patient inclusion	2
Table 1	Missing data	3
Table 2	Baseline characteristics stratified according to the need of ICU treatment	6
Table 3	Baseline medication in patients with and without acute ischemic stroke	8
Table 4	Baseline characteristics stratified according to age groups	10
Table 5	Sensitivity analysis excluding centers that included patients with cardiovascular risk factors only	12
Table 6	Occurrence of other thromboembolic complications in patients with and without acute ischemic stroke stratified by etiology of stroke	14
Table 7	Occurrence of other thromboembolic complications in patients with and without acute ischemic stroke stratified by age and sex	16
Table 8	In-hospital mortality in patients with COVID-19 with an ischemic stroke according to the need of ICU treatment and stratified by age and sex	17
Table 9	List of participating organizations in CAPACITY COVID	18

Figure 1. Flowchart of patient inclusion




Table 1. Missing data

Characteristics	Missing values (%)
Age, years (mean; SD)	0
Sex (female)	0
BMI, kg/m ² (mean; SD)	359 (16.7)
Ethnicity	358 (16.7)
Medical history	
Hypertension	48 (2.2)
Diabetes	16 (0.7)
Hyperlipidemia	181 (8.4)
Peripheral artery disease	179 (8.3)
Coronary artery disease	184 (8.6)
Valvular heart disease	0
Heart failure	0
Atrial fibrillation	0
Venous thromboembolism	184 (8.6)
Chronic kidney disease	6 (0.3)
Inflammatory disease	5 (0.2)
COPD	4 (0.2)
TIA and/or Ischemic stroke	0
Intracerebral hemorrhage	1 (<0.1)
Subarachnoid hemorrhage	1 (<0.1)

Baseline medication

Betablockers	3 (0.1)
Anti-arrhythmic drugs	3 (0.1)
Digoxin	3 (0.1)
Diuretics	3 (0.1)
Calciumchannel blockers	3 (0.1)
ACE inhibitors	3 (0.1)
Angiotensin receptor blocker	3 (0.1)
Aldosteron antagonists	3 (0.1)
Coumarins	3 (0.1)
DOAC	3 (0.1)
Lipid lowering medication	3 (0.1)
Insulin	3 (0.1)
Oral anti diabetics	3 (0.1)
Anti-platelet therapy*	5 (0.2)
Dual platelet therapy†	2 (0.3)

In-hospital complications

Deep venous thromboembolism	0
Pulmonary embolism	0
Atrial fibrillation	0
Cardiac ischaemia	0
Endocarditis	0
Acute ischemic stroke	0
In-hospital mortality	0

* usage of anti-platelet therapy in general. † usage of more than one anti-platelet drug.

Abbreviations: SD = standard deviation, BMI = body mass index, COPD = chronic obstructive pulmonary disease, TIA = transient ischemic attack, ACE = angiotensin converting enzyme, DOAC = direct oral anticoagulant, AIS = acute ischemic stroke.

Table 2. Baseline characteristics stratified according to the need of ICU treatment

Characteristics*	ICU treatment	No ICU treatment	p-value
	n=586	n=1561	
Age, years (median; IQR)	66.0 (58.0-72.3)	73.0 (60.0-80.0)	p = <0.001
Sex (female)	157 (26.8)	612 (39.2)	p = <0.001
BMI, kg/m ² (mean; SD)	28.5 (4.8)	27.7 (5.1)	p = 0.002
Medical history			
Hypertension	240 (41.0)	794 (50.9)	p = <0.001
Diabetes	141 (24.1)	427 (27.4)	p = 0.293
Hyperlipidemia	200 (34.1)	662 (42.4)	p = <0.001
Peripheral artery disease	32 (5.8)	100 (7.1)	p = 0.301
Coronary artery disease	95 (16.2)	353 (22.6)	p = 0.001
Valvular heart disease	18 (3.1)	120 (7.7)	p = <0.001
Heart failure	17 (2.9)	137 (8.8)	p = <0.001
Atrial fibrillation	52 (8.9)	230 (14.7)	p = <0.001
Venous thromboembolism	20 (3.4)	71 (4.5)	p = <0.001
Chronic kidney disease	44 (7.5)	236 (15.1)	p = <0.001
Inflammatory disease	48 (8.2)	210 (13.5)	p = 0.003
COPD	47 (8.0)	204 (13.1)	p = 0.005
TIA and/or Ischemic stroke	52 (8.9)	225 (14.4)	p = <0.001
Intracerebral hemorrhage	4 (0.7)	13 (0.8)	p = 0.248
Subarachnoid hemorrhage	2 (0.3)	4 (0.3)	p = 0.249

*Numbers are n (%) unless otherwise stated.

Abbreviations: ICU = critical or intensive care unit, IQR = interquartile range, SD = standard deviation, BMI = body mass index, COPD = chronic obstructive pulmonary disease, TIA = transient ischemic attack.

Table 3. Baseline medication in patients with and without acute ischemic stroke

Baseline medication*	Total cohort	No ischemic stroke	Ischemic stroke	p-value
	n=2147	n=2109	n=38	
Betablockers	653 (30.4)	642 (30.4)	11 (28.9)	p = 0.953
Anti-arrhythmic drugs	91 (4.2)	90 (4.3)	1 (2.6)	p = 0.860
Digoxin	47 (2.2)	47 (2.2)	0	p = 0.631
Diuretics	523 (24.4)	515 (24.4)	8 (21.1)	p = 0.866
Calciumchannel blockers	348 (16.2)	345 (16.4)	3 (7.9)	p = 0.362
ACE inhibitors	422 (19.7)	416 (19.7)	6 (15.8)	p = 0.808
Angiotensin receptor blocker	312 (14.5)	306 (14.5)	6 (15.8)	p = 0.950
Aldosteron antagonists	71 (3.3)	71 (3.4)	0	p = 0.501
Coumarins	163 (7.6)	160 (7.6)	3 (7.9)	p = 0.971
DOAC	201 (9.4)	197 (9.3)	4 (10.5)	p = 0.944
Lipid lowering medication	839 (39.1)	823 (39.0)	16 (42.1)	p = 0.906
Insulin	183 (8.5)	181 (8.6)	2 (5.3)	p = 0.746
Oral anti diabetics	377 (17.6)	371 (17.6)	6 (15.8)	p = 0.932

Anti-platelet therapy	639 (29.8)	629 (29.8)	10 (26.3)	p = 0.852
Dual platelet therapy	57 (8.9)	55 (8.8)	2 (20.0)	p = 0.217

*Numbers are n (%).

Abbreviations: ACE = angiotensin converting enzyme, DOAC = direct oral anticoagulant.

Table 4. Baseline characteristics stratified according to age groups

Characteristics*	Age <50 years		Age 50-69 years		Age ≥70 years	
	No ischemic stroke n= 202	Ischemic stroke n= 2	No ischemic stroke n= 805	Ischemic stroke n= 11	No ischemic stroke n= 1102	Ischemic stroke n= 25
Medical history						
Hypertension	35 (17.3)	0	312 (38.8)	3 (27.3)	673 (61.1)	11 (44.0)
Diabetes	33 (16.3)	1 (50.0)	179 (22.2)	0	348 (31.6)	7 (28.0)
Hyperlipidemia	22 (10.9)	1 (50.0)	267 (33.2)	5 (45.5)	558 (50.6)	9 (36.0)
Peripheral artery disease	6 (3.1)	0	30 (4.0)	1 (12.5)	91 (9.3)	4 (16.7)
Coronary artery disease	4 (2.0)	0	117 (14.5)	1 (9.1)	322 (29.2)	4 (16.0)
Valvular heart disease	0	0	18 (2.2)	0	118 (10.7)	2 (8.0)
Heart failure	1 (0.5)	0	22 (2.7)	0	130 (11.8)	1 (4.0)
Atrial fibrillation	1 (0.5)	0	38 (4.7)	0	239 (21.7)	4 (16.0)
Venous embolism	2 (1.0)	0	29 (3.6)	0	57 (5.2)	3 (12.0)
Chronic kidney disease	12 (5.9)	0	52 (6.5)	1 (9.1)	213 (19.3)	2 (8.0)

Inflammatory disease	23 (11.4)	0	91 (11.3)	1 (9.1)	140 (12.7)	3 (12.0)
COPD	3 (1.5)	0	71 (8.8)	2 (18.2)	171 (15.5)	4 (16.0)
TIA / Ischemic stroke	4 (2.0)	0	59 (7.3)	2 (18.2)	208 (18.9)	4 (16.0)
Intracerebral hemorrhage	0	0	6 (0.7)	0	11 (1.0)	0
Subarachnoid hemorrhage	0	0	3 (0.4)	0	3 (0.3)	0

*Numbers are n (%) unless otherwise stated.

Abbreviations: COPD = chronic obstructive pulmonary disease, TIA = transient ischemic attack.

Table 5. Sensitivity analysis excluding centers that included patients with cardiovascular risk factors only

Characteristics*	Total cohort	No ischemic stroke	Ischemic stroke	p-value
n	1846	1810 (98.0)	36 (2.0)	
Age, years (median; IQR)	70.0 (59.0-77.0)	70.0 (59.0-77.0)	74.0 (66.3-82.0)	p = <0.001
Sex (female)	667 (36.1)	653 (36.1)	14 (38.9)	p = 0.728
BMI, kg/m ² (mean; SD)	27.9 (5.1)	27.9 (5.1)	25.8 (4.4)	p = 0.025
Medical history				
Hypertension	852 (47.3)	840 (47.6)	12 (34.3)	p = 0.119
Diabetes	480 (26.2)	473 (26.3)	7 (19.4)	p = 0.354
Hyperlipidemia	721 (39.1)	706 (39.0)	15 (41.7)	p = 0.947
Peripheral artery disease	116 (6.5)	111 (6.4)	5 (15.2)	p = 0.043
Coronary artery disease	352 (19.1)	347 (19.2)	5 (13.9)	p = 0.424
Valvular heart disease	112 (6.1)	110 (6.1)	2 (5.6)	p = 0.897
Heart failure	128 (6.9)	128 (7.1)	0 (0.0)	p = 0.098
Atrial fibrillation	242 (13.1)	239 (13.2)	3 (8.3)	p = 0.391
Venous thromboembolism	82 (4.4)	79 (4.4)	3 (8.3)	p = 0.456

Chronic kidney disease	224 (12.1)	222 (12.3)	2 (5.6)	p = 0.469
Inflammatory disease	223 (12.1)	220 (12.2)	3 (8.3)	p = 0.776
COPD	212 (11.5)	207 (11.4)	5 (13.9)	p = 0.648
TIA and/or Ischemic stroke	239 (12.9)	233 (12.9)	6 (16.7)	p = 0.502
Intracerebral hemorrhage	15 (0.8)	15 (0.8)	0 (0.0)	p = 0.583
Subarachnoid hemorrhage	4 (0.2)	4 (0.2)	0 (0.0)	p = 0.778

*Numbers are n (%) unless otherwise stated.

Abbreviations: ICU = critical or intensive care unit, SD = standard deviation, BMI = body mass index, COPD = chronic obstructive pulmonary disease, TIA = transient ischemic attack.

Table 6. Occurrence of other thromboembolic complications in patients with and without acute ischemic stroke stratified by etiology

Characteristics*	Total cohort (%)	Cryptogenic (%)	Known etiology (%)
	n=38	n=18	n=20
Age, years (median; IQR)	74.5 (66.8-82.0)	71.5 (64.3-81.0)	80.0 (67.0-82.0)
Female sex	16 (42.1)	8 (44.4)	8 (40.0)
Prior antiplatelet use	10 (26.3)	6 (33.3)	4 (20.0)
Prior anticoagulant use	7 (18.4)	0 (0.0)	7 (35.0)
<hr/>			
Time to diagnosis (median; IQR)			
Symptom to stroke [†]	14.0 (7.5-26.3)	23.0 (8.5-30.0)	11.5 (7.5-15.8)
Stroke symptoms as presenting complaint	4 (10.5)	1 (5.5)	3 (15.0)
Treatment at ICU	16 (42.1)	10 (55.6)	6 (30.0)
<hr/>			
NIHSS (median; IQR)	8.5 (3.0-23.8)	16.5 (4.5-30.0)	5.0 (2.3-20.0)
<hr/>			
<i>Hemisphere</i>			
Left	17 (44.7)	6 (33.3)	11 (55.0)
Right	12 (31.6)	7 (38.9)	5 (25.0)
Both	6 (15.8)	4 (22.2)	2 (10.0)

Infratentorial	3 (7.9)	1 (5.6)	2 (10.0)
<hr/>			
<i>Large vessel occlusion</i>			
Yes	10 (26.3)	4 (22.2)	6 (30.0)
No	11 (28.9)	5 (27.8)	6 (30.0)
No angiography	17 (44.7)	9 (50.0)	8 (40.0)
<hr/>			
<i>Reperfusion therapy</i>			
IVT	2 (5.3)	1 (5.6)	1 (5.0)
EVT	5 (13.2)	3 (16.7)	2 (10.0)
<hr/>			
Occurrence of another TE event	10 (26.3)	6 (33.3)	4 (20.0)
Unfavorable outcome [‡]	27 (71.1)	14 (77.8)	13 (65.0)
In-hospital mortality	20 (52.6)	10 (55.6)	10 (50.0)

* All numbers are N (%) unless otherwise stated.

† Days from first COVID symptoms to diagnosis of ischemic stroke;

‡ Defined as death or dependency, modified Rankin scale 3 or higher

Abbreviations: IQR = interquartile range, NIHSS = national institute of health stroke scale, IVT = intravenous therapy, EVT = endovascular therapy, TOAST = trial of ORG 10172 in acute stroke treatment. TE=thromboembolic.

Table 7. Occurrence of other thromboembolic complications in patients with and without ischemic stroke stratified by age and sex

	Total (n)	DVT (%)		PE (%)		AF (%)		Cardiac ischemia (%)		Endocarditis (%)	
		No AIS	AIS	No AIS	AIS	No AIS	AIS	No AIS	AIS	No AIS	AIS
Overall	2147	11 (0.5)	0	160 (7.6)	8 (21.1)	145 (6.9)	4 (10.5)	36 (1.7)	2 (5.3)	2 (0.1)	0
Stratified by sex											
Females	769	2 (0.3)	0	35 (4.6)	4 (25.0)	44 (5.8)	2 (12.5)	7 (0.9)	29 (2.1)	1 (0.1)	0
Males	1378	9 (0.7)	0	125 (9.2)	4 (18.2)	101 (7.4)	2 (9.1)	29 (2.1)	2 (9.1)	1 (0.1)	0
Stratified by age											
<50 years	204	1 (0.5)	0	10 (5.0)	1 (50.0)	2 (1.0)	0	0	0	0	0
50-69 years	816	8 (1.0)	0	93 (11.6)	5 (45.5)	53 (6.6)	1 (9.1)	18 (2.2)	1 (9.1)	1 (0.1)	0
≥70 years	1127	2 (0.2)	0	57 (5.2)	2 (8.0)	90 (8.2)	3 (12.0)	18 (1.6)	1 (4.0)	1 (0.1)	0

*Numbers are n (%).

Abbreviations: AIS = acute ischemic stroke, DVT = deep vein thrombosis, PE = pulmonary embolism, AF = atrial fibrillation.

Table 8. In-hospital mortality in patients with COVID-19 with an ischemic stroke according to the need of ICU treatment and stratified by age and sex

	Total cohort (%; 95%CI)	ICU treatment (%; 95%CI)	General ward (%; 95%CI)
Total	20/38 (52.6; 37.3-67.5)	7/16 (43.8; 0.23-0.67)	13/22 (59.1; 0.39-0.77)
Stratified by sex			
Female	7/16 (43.8; 0.23-0.67)	1/6 (16.7; 3.0-56.4)	6/10 (60.0; 31.1-83.2)
Male	13/22 (59.1; 0.39-0.77)	6/10 (60.0; 31.1-83.2)	7/12 (58.3; 32.0-80.7)
Stratified by age			
<50 years	1/2 (50.0; 9.5-90.6)	1/2 (50.0; 9.5-90.6)	0
50-69 years	4/11 (36.4; 15.2-64.6)	3/9 (33.3; 12.1-64.6)	1/2 (50.0; 9.5-90.6)
≥70 years	15/25 (60.0; 40.7-76.6)	3/5 (60.0; 23.1-88.2)	12/20 (60.0; 38.7-78.1)

Numbers are n (%; 95%CI).

Abbreviations: CI = confidence interval

Table 9. List of participating and endorsing organizations in CAPACITY COVID

Dutch CardioVascular Alliance (DCVA)

The Dutch Association of Medical Specialists (FMS)

The British Heart Foundation Centres of Research Excellence.

The European Society of Cardiology (ESC)

The European Heart Network (EHN)

The Society for Cardiovascular Magnetic Resonance (SCMR)

The Dutch Society of Neurology

Kennisnetwerk CVA NL